Delivery Order HHSN261201200031I-HHSN26100010
Award Date
9/24/15
Potential Completion Date
9/23/19
Potential Value
$2.9M
Federal Agency
National Cancer Institute
Awardee
University Of Arizona
Ultimate Awardee
State Of Arizona
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Tucson, AZ 85719, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
5
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $580,503.00 delivery order award under the Cancer Prevention Agent Development Program 2012-2017 indefinite delivery contract issued by the National Cancer Institute, a component of the U.S. Department of Health and Human Services. The order was awarded to the University of Arizona, doing business as the Arizona Board of Regents, for research and development services to support core infrastructure for the agency's cancer prevention agent development efforts. The work will be...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Delivery Order contract to the University of Arizona, doing business as the Arizona Board of Regents, to provide core infrastructure support for the Cancer Prevention Agent Development Program. The $1,535,496.00 contract has a performance period ending on September 22, 2023 and does not utilize a set-aside designation. This Delivery Order is part of the larger Cancer Prevention Agent...
This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Arizona, doing business as the Arizona Board of Regents. The $151,603.00 delivery order supports the "UNIVERSITY OF CALIFORNIA AT IRVINE CLINICAL TRIAL SUPPORT" effort under the Cancer Prevention Agent Development Program 2012-2017, a major NCI program focused on early-phase clinical cancer research. This contract does...
This is a federal contract award to the University of Arizona, doing business as the Arizona Board of Regents, by the National Cancer Institute (NCI). The $796,585.45 contract is for a clinical study of Avmacol, a product aimed at detoxifying tobacco carcinogens in heavy smokers. This award is part of the NCI's Cancer Prevention Agent Development Program, which funds early-phase clinical research. The contract is a delivery order under a master Indefinite Delivery/Indefinite Quantity (IDIQ)...
This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Arizona. The contract, valued at $812,957.75, is for a delivery order under the Cancer Prevention Agent Development Program 2012-2017 master IDIQ contract. The purpose of the award is for the "M4OC-PREVENT: METFORMIN FOR ORAL CANCER PREVENTION" project, which is part of the NCI's Cancer Prevention Agent Development...
This is a delivery order under the Cancer Prevention Agent Development Program 2012-2017 IDIQ contract, awarded by the National Cancer Institute to the University of Arizona for a value of $1,027,142.83. The contract is for the development of topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) grades 2-3, with a period of performance through September 15, 2023. The contract does not have a set-aside designation. The University of Arizona has subcontracted a portion of...
This federal contract award, valued at $2,843,821, was issued by the National Cancer Institute to the University of Arizona, doing business as the Arizona Board of Regents, for a prospective Phase IIa clinical trial to assess the immunogenicity of a nonavalent prophylactic HPV vaccine using a prime and deferred-booster dosing schedule in 9-12 year old girls. The award is part of the Cancer Prevention Agent Development Program, which supports early-phase clinical trials. This is not a set-aside...
This is a federal contract award from the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to the University of Arizona, a public research university and land grant institution, for a clinical study on the effects of combined aspirin and zileuton treatment on tobacco-related carcinogenesis biomarkers in current smokers. The $1,476,557 award falls under the Cancer Prevention Agent Development Program 2012-2017 indefinite delivery vehicle, and has...
This federal contract award is for the National Cancer Institute's Cancer Prevention Agent Development Program. The prime contractor is The University of Texas M.D. Anderson Cancer Center, a comprehensive cancer research and treatment center. The contract has a ceiling value of $4,248,160.62 and does not use a set-aside designation. The contract supports early phase clinical research, with the objective of developing cancer prevention agents. It includes subcontracts with several universities...
The University of Arizona, doing business as the Arizona Board of Regents, has been awarded a $2,789,411.92 cost-type delivery order contract by the National Cancer Institute (NCI) to conduct a Phase II randomized, placebo-controlled clinical trial of the prostate cancer vaccine Prostvac (PSA-TRICOM) in patients with clinically localized prostate cancer undergoing active surveillance. This contract supports the NCI's Cancer Prevention Agent Development Program 2012-2017 and does not have a...